The global GLP-1 receptor agonist market is poised for significant growth, expanding from an estimated USD 49.3 billion in 2024 to USD 157.5 billion by 2035, reflecting a compound annual growth rate (CAGR) of 11.1% over this period. This robust expansion is driven by increasing demand for treatments targeting type 2 diabetes and obesity, alongside emerging applications in other health conditions.

Market Growth Drivers

GLP-1 drugs primarily manage blood glucose levels in individuals with type 2 diabetes and have shown efficacy in treating obesity and related cardiovascular diseases. The rising prevalence of obesity—affecting 42.4% of U.S. adults—and diabetes, with nearly 530 million adults affected globally (98% with type 2 diabetes), underpins the growing market demand. The World Health Organization reports that obesity causes approximately 4 million deaths annually, while diabetes remains a leading cause of mortality worldwide.

Lifestyle changes influenced by social media, celebrity endorsements, and direct-to-consumer advertising have further accelerated demand for GLP-1 therapies, especially for weight management. The market has benefited from continuous research and positive clinical trial outcomes, fostering innovation and expanding treatment options beyond diabetes to obesity and cardiovascular risk reduction.

Market Segmentation

- Type of Molecule: The market is segmented into biologics and small molecules. Small molecules currently hold the largest market share, but biologics are expected to grow substantially due to their superior selectivity, specificity, and stability.

- Active Compounds: Semaglutide and tirzepatide dominate the market. Semaglutide is marketed under Ozempic, Rybelsus (the only oral GLP-1 agonist), and Wegovy, while tirzepatide is available as Mounjaro and Zepbound. Emerging compounds like retatrutide and survodutide are anticipated to gain significant market share in the future.

- Type of GLP-1 Agonist Drugs: Long-acting GLP-1 agonists currently dominate due to their prolonged effects compared to short-acting formulations.

- Route of Administration: Oral administration is growing faster (CAGR of 16.7%) than parenteral routes, driven by convenience and safety considerations.

- Target Indications: While type 2 diabetes currently accounts for the largest share, the obesity segment is expected to become the largest by 2035, growing at a CAGR of 19.2%, reflecting the high global incidence of obesity and lifestyle shifts.

- Geographical Distribution: North America holds the largest market share (approximately 73%), supported by strong demand influenced by social media and direct advertising. Asia-Pacific is the fastest-growing region with a projected CAGR of 14.6%, driven by improved insurance coverage and increasing adoption.

Emerging Applications

Beyond diabetes and obesity, GLP-1 therapies are being explored for additional indications such as Alzheimer’s disease, non-alcoholic steatohepatitis (NASH), sleep apnea, and potentially neurodegenerative disorders. Research indicates GLP-1 receptor agonists possess anti-inflammatory, neuroprotective, and neurotrophic properties, which may benefit Alzheimer’s disease by reducing inflammation, aiding beta-amyloid clearance, and improving brain health. Real-world studies have linked semaglutide with a 40% to 70% reduction in Alzheimer’s risk among type 2 diabetes patients.

Challenges

Patent expirations pose a challenge but also an opportunity. For example, Novo Nordisk’s Victoza (liraglutide) patent expired in November 2024, and authorized generics have entered the market. Semaglutide’s patent exclusivity is set to expire in March 2026, with generic versions expected to increase affordability and accessibility, potentially expanding the overall market despite price competition.

Key Players and Competitive Landscape

The GLP-1 market features around 60 companies, including major pharmaceutical firms such as Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Pfizer, and Sanofi. Novo Nordisk leads with five GLP-1 branded drugs, including three for diabetes and two for weight loss. The company reported a 64.4% growth in its GLP-1 portfolio in 2023, with Wegovy experiencing over 400% growth.

Increasing partnerships and licensing agreements are common strategies among developers to enhance drug portfolios and accelerate market growth. Recent collaborations include Sciwind Biosciences’ licensing deal with HK inno.N for ecnoglutide in South Korea and strategic agreements for manufacturing expansion by companies like Amneal Pharmaceuticals and Corden Pharma.

Conclusion

The GLP-1 receptor agonist market is on a strong growth trajectory fueled by rising prevalence of diabetes and obesity, expanding therapeutic indications, and innovation in drug formulations and delivery methods. With ongoing research uncovering broader health benefits, including potential neuroprotective effects, and increasing global adoption, the GLP-1 market is set to transform chronic disease management significantly over the next decade.

Thank you for reading Roots Analysis report. Kindly get in touch with Roots’ team to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.

URL: https://www.rootsanalysis.com/reports/glp-1-market.html

About Roots Analysis

Roots Analysis is a global leader in market research, competitive intelligence and consulting services across industries. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, and venture and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serving our clients in the best possible way.

Contact Details

Roots Analysis

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com

Website: https://www.rootsanalysis.com/